CN109172575A - 基于阿拉莫林的药物治疗 - Google Patents

基于阿拉莫林的药物治疗 Download PDF

Info

Publication number
CN109172575A
CN109172575A CN201811119404.7A CN201811119404A CN109172575A CN 109172575 A CN109172575 A CN 109172575A CN 201811119404 A CN201811119404 A CN 201811119404A CN 109172575 A CN109172575 A CN 109172575A
Authority
CN
China
Prior art keywords
patient
anamorelin
cancer
purposes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811119404.7A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·曼
约翰·弗兰德
威廉·波尔维诺
苏珊·艾伦
陆明
伊丽莎白·杜斯
鲁本·焦尔吉诺
恩里科·布洛尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heersen Health Care Co Ltd
Helsinn Healthcare SA
Original Assignee
Heersen Health Care Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109172575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heersen Health Care Co Ltd filed Critical Heersen Health Care Co Ltd
Publication of CN109172575A publication Critical patent/CN109172575A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201811119404.7A 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗 Pending CN109172575A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
CN201580059744.3A CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580059744.3A Division CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Publications (1)

Publication Number Publication Date
CN109172575A true CN109172575A (zh) 2019-01-11

Family

ID=55436476

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201811119404.7A Pending CN109172575A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111026050.3A Pending CN113577073A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201710646685.0A Pending CN107375285A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201580059744.3A Pending CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111027023.8A Pending CN113577074A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202111026050.3A Pending CN113577073A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201710646685.0A Pending CN107375285A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN201580059744.3A Pending CN107205389A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗
CN202111027023.8A Pending CN113577074A (zh) 2014-09-04 2015-08-28 基于阿拉莫林的药物治疗

Country Status (44)

Country Link
US (5) US9675600B2 (OSRAM)
EP (2) EP3188599B1 (OSRAM)
JP (3) JP6356907B2 (OSRAM)
KR (3) KR102307275B1 (OSRAM)
CN (5) CN109172575A (OSRAM)
AP (1) AP2017009772A0 (OSRAM)
AR (1) AR103118A1 (OSRAM)
AU (1) AU2015312231B2 (OSRAM)
BR (1) BR112017003552A2 (OSRAM)
CA (1) CA2959158A1 (OSRAM)
CL (1) CL2017000494A1 (OSRAM)
CO (1) CO2017003263A2 (OSRAM)
CR (1) CR20170121A (OSRAM)
CY (1) CY1122746T1 (OSRAM)
DK (1) DK3188599T3 (OSRAM)
DO (1) DOP2017000055A (OSRAM)
EA (1) EA035578B1 (OSRAM)
EC (1) ECSP17019893A (OSRAM)
ES (1) ES2761777T3 (OSRAM)
GE (2) GEP20186939B (OSRAM)
HR (1) HRP20192345T1 (OSRAM)
HU (1) HUE046894T2 (OSRAM)
IL (1) IL250692B (OSRAM)
JO (1) JO3541B1 (OSRAM)
LT (1) LT3188599T (OSRAM)
MA (1) MA40607B1 (OSRAM)
MD (1) MD4710C1 (OSRAM)
ME (1) ME03597B (OSRAM)
MX (1) MX361741B (OSRAM)
MY (1) MY187167A (OSRAM)
NI (1) NI201700024A (OSRAM)
PE (1) PE20171109A1 (OSRAM)
PH (1) PH12017500392B1 (OSRAM)
PL (1) PL3188599T3 (OSRAM)
PT (1) PT3188599T (OSRAM)
RS (1) RS59751B1 (OSRAM)
SG (1) SG11201701567UA (OSRAM)
SI (1) SI3188599T1 (OSRAM)
SV (1) SV2017005400A (OSRAM)
TN (1) TN2017000040A1 (OSRAM)
TW (1) TWI639429B (OSRAM)
UA (1) UA120765C2 (OSRAM)
UY (1) UY36286A (OSRAM)
WO (1) WO2016036598A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
WO2020132341A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
BR112022002767A2 (pt) 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer
WO2021079978A1 (ja) * 2019-10-24 2021-04-29 東レ株式会社 悪液質の治療剤又は予防剤
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
WO2005014032A2 (en) 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) * 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CURROW DC等: "Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome", 《FUTURE ONCOLOGY》 *
JM GARCIA等: "Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study", 《CANCER & METABOLISM》 *
周道安等: "《新编肺癌综合治疗学》", 30 September 2009, 复旦大学出版社 *
唐锡麟: "《儿童少年卫生学》", 30 November 1986, 人民卫生出版社 *
林丽珠: "《肿瘤中西医治疗学》", 30 September 2013, 人民军医出版社 *

Also Published As

Publication number Publication date
JP2018154655A (ja) 2018-10-04
EP3188599A4 (en) 2017-10-11
MD4710C1 (ro) 2021-04-30
JP7044918B2 (ja) 2022-03-30
TW201613587A (en) 2016-04-16
US9675600B2 (en) 2017-06-13
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
US20190175574A1 (en) 2019-06-13
EP3188599B1 (en) 2019-10-02
US20210093627A1 (en) 2021-04-01
MD4710B1 (ro) 2020-09-30
MX2017002825A (es) 2017-09-28
PH12017500392A1 (en) 2017-07-17
IL250692B (en) 2019-05-30
RS59751B1 (sr) 2020-02-28
PT3188599T (pt) 2020-01-15
BR112017003552A2 (pt) 2017-12-05
NI201700024A (es) 2017-07-18
UY36286A (es) 2016-02-29
CN107205389A (zh) 2017-09-26
MA40607B1 (fr) 2019-11-29
JP2021080281A (ja) 2021-05-27
US10278964B2 (en) 2019-05-07
ECSP17019893A (es) 2017-05-31
NZ729673A (en) 2023-09-29
CA2959158A1 (en) 2016-03-10
PH12017500392B1 (en) 2018-08-31
SI3188599T1 (sl) 2020-02-28
AU2015312231A1 (en) 2017-03-23
CN113577073A (zh) 2021-11-02
ME03597B (me) 2020-07-20
WO2016036598A1 (en) 2016-03-10
US20240024303A1 (en) 2024-01-25
GEAP201814459A (en) 2018-09-10
AR103118A1 (es) 2017-04-19
TN2017000040A1 (en) 2018-07-04
KR102234319B1 (ko) 2021-04-01
IL250692A0 (en) 2017-04-30
PL3188599T3 (pl) 2020-06-01
SV2017005400A (es) 2017-04-20
PE20171109A1 (es) 2017-08-07
HUE046894T2 (hu) 2020-04-28
KR101881264B1 (ko) 2018-07-23
MD20170025A2 (ro) 2017-07-31
UA120765C2 (uk) 2020-02-10
KR20180085047A (ko) 2018-07-25
EP3188599A1 (en) 2017-07-12
AU2015312231B2 (en) 2017-10-19
ES2761777T3 (es) 2020-05-21
CN113577074A (zh) 2021-11-02
MX361741B (es) 2018-12-14
CO2017003263A2 (es) 2017-07-28
DOP2017000055A (es) 2017-08-15
US10894041B2 (en) 2021-01-19
US20160067236A1 (en) 2016-03-10
KR102307275B1 (ko) 2021-09-30
KR20210035923A (ko) 2021-04-01
HRP20192345T1 (hr) 2020-03-20
JP2017526695A (ja) 2017-09-14
CY1122746T1 (el) 2021-03-12
CL2017000494A1 (es) 2017-09-15
CR20170121A (es) 2017-07-17
JO3541B1 (ar) 2020-07-05
KR20170047372A (ko) 2017-05-04
JP6356907B2 (ja) 2018-07-11
US11723902B2 (en) 2023-08-15
CN107375285A (zh) 2017-11-24
MY187167A (en) 2021-09-07
LT3188599T (lt) 2019-12-10
AP2017009772A0 (en) 2017-02-28
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
SG11201701567UA (en) 2017-03-30
US20170296526A1 (en) 2017-10-19
EP3590338A2 (en) 2020-01-08
JP6923486B2 (ja) 2021-08-18
EP3590338A3 (en) 2020-03-18
TWI639429B (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
CN109172575A (zh) 基于阿拉莫林的药物治疗
Zaidi et al. Efficacy of complementary therapies in the quality of life of breast cancer survivors
US20240390319A1 (en) Terpene Control in Scaleable Cannabinoids Medicinal Formulations
Schukro et al. The effects of auricular electroacupuncture on obesity in female patients–a prospective randomized placebo-controlled pilot study
WO2019171352A2 (en) Methods of treating severe non-diabetic obesity
HK40020876A (en) Medical treatments based on anamorelin
HK1234959B (en) Medical treatments based on anamorelin
HK1234959A1 (en) Medical treatments based on anamorelin
NZ729673B2 (en) Medical treatments based on anamorelin
OA18229A (en) Medical treatments based on anamorelin.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190111